Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy

American Journal of Health-System Pharmacy

Volumn 62, Issue 15, 2005, Pages 1596-1605

  Bond, C A ^a,b   Raehl, Cynthia L ^b  

^a Department of Pharmacy ^*  (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Aminoglycosides; Antibiotics; Drug use; Economics; Health benefit programs; Hospitals; Infections; Interventions; Mortality; Outcomes; Pharmaceutical services; Pharmacists, hospital; Pharmacy, institutional, hospital; Rational therapy; Toxicity; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; VANCOMYCIN;

ARTICLE; BACTEREMIA; CONTROLLED STUDY; DRUG COST; ECONOMIC ASPECT; ENDOCARDITIS; HEALTH CARE; HEARING LOSS; HUMAN; KIDNEY DISEASE; LENGTH OF STAY; MEDICARE; MORTALITY; NEPHROTOXICITY; PHARMACIST; PHARMACY; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; SEPSIS;

EID: 23044433603     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040555     Document Type: Article

References (79)

1. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: monitoring and patient education-2003. Am J Health-Syst Pharm. 2004; 61:457-71.
2. McGlynn EA, Asch SM, Adams I et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003; 348:2635-45.
3. Committee on Enhancing Federal Health Care Quality Programs. Leadership by example: coordinating government roles in improving health care quality. Washington, DC: National Academy Press; 2003:1.
4. Committee on the Quality of Care in America. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academy Press; 2001:1.
5. Expanded modified Medicare provider analysis and review (MedPAR-Hospital {national} FY 1995). Baltimore, MD: Centers for Medicare and Medicaid Services; 1995. Tape cartridges.
6. Hatoum HT, Catizone C, Hutchinson RA et al. An eleven-year review of the pharmacy literature: documentation of the value and acceptance of clinical pharmacy. Drug Intell Clin Pharm. 1986; 20:33-48.
7. Black BL. Resource book on progressive pharmaceutical services. Bethesda, MD: American Society of Hospital Pharmacists; 1986:1-121.
8. Comptroller General of the United States. Study of health facilities construction costs. Washington, DC: U.S. Government Printing Office; 1972:68-72,363-79.
9. Barker KN, Pearson RE. Medication distribution systems. In: Brown TR, Smith MC, eds. Handbook of institutional pharmacy practice. Baltimore: Williams & Wilkins; 1986:325-51.
10. Elenbaas RM, Payne VW, Bauman JL. Influence of clinical pharmacists consultations on the use of drug blood level tests. Am J Hosp Pharm. 1980; 37:61-4.
11. Bollish SJ, Kelly WN, Miller DE et al. Establishing an aminoglycoside pharmacokinetic monitoring service in a community hospital. Am J Hosp Pharm. 1981; 38: 73-6.
12. Abramowitz PA, Nold EC, Hatfield SM. Use of clinical pharmacists to reduce cefamandole, cefoxitin, and ticarcillin costs. Am J Hosp Pharm. 1982; 39:1176-80.
13. Mutchie KD, Smith KA, MacKay MW et al. Pharmacist monitoring of parenteral nutrition: clinical and cost effectiveness. Am J Hosp Pharm. 1979; 36:785-7.
14. Bond CA, Salinger RJ. Fluphenazine outpatient clinics: a pharmacist's role. J Clin Psychiatry. 1979; 40:501-3.
15. Covinsky JO, Hamburger SC, Kelly KL et al. Impact of the docent clinical pharmacist on treatment of streptococcal pneumonia. Drug Intell Clin Pharm. 1982; 16:587-91.
16. Herfindal ET, Bernstein LR, Kishi DT. Effect of clinical pharmacy services on prescribing on an orthopedic unit. Am J Hosp Pharm. 1983; 40:1945-51.
17. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach: a randomized controlled trial of academically based "detailing." N Engl J Med. 1983; 308:1457-63.
18. Knapp DE, Knapp DA, Speedie MK et al. Relationship of inappropriate drug prescribing to increased length of hospital stay. Am J Hosp Pharm. 1979; 36:1334-7.
19. Knapp DE, Speedie MK, Yaeger DM et al. Drug prescribing and its relationship to length of hospital stay. Inquiry. 1980; 17:254-9.
20. McKenney JM, Wasserman AH. Effect of advanced pharmaceutical services on the incidence of adverse drug reactions. Am J Hosp Pharm. 1979; 36:1691-7.
21. Clapham CE, Hepler CE, Reinders TP et al. Economic consequences of two drug-use control systems in a teaching hospital. Am J Hosp Pharm. 1988; 45:2329-40.
22. Bjornson DC, Hiner WO Jr, Potyk RP et al. Effect of pharmacists on health care outcomes in hospitalized patients. Am J Hosp Pharm. 1993; 50:1875-84.
23. Jenkins MH, Bond CA. The impact of clinical pharmacists on psychiatric patients. Pharmacotherapy. 1996; 16:708-14.
24. Monson RA, Bond CA, Schuna A. Role of the clinical pharmacist in improving outpatient drug therapy. Arch Intern Med. 1981; 141:1441-4.
25. Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control-a four year ambulatory care model. Arch Intern Med. 1984; 144:1159-62.
26. Tang I, Vrahnos D, Hatoum H et al. Effectiveness of clinical pharmacist interventions in a hemodialysis unit. Clin Ther. 1993; 15:459-64.
27. Brown WJ. Pharmacist participation on a multidisciplinary rehabilitation team. Am J Hosp Pharm. 1994; 51:91-2.
28. Watts CA, Klastorin TD. The impact of case mix on hospital costs: a comparative analysis. Inquiry. 1980; 17:357-67.
29. Schumock GT, Meek PD, Ploetz PA et al. Economic evaluation of clinical pharmacy services-1988-1995. Pharmacotherapy. 1996; 16:1188-208.
30. Gattis WA, Hasselblad V, Whellan DJ et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study. Arch Intern Med. 1999; 159:1939-45.
31. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70.
32. Kaushal R, Bates DW, Landrigan C et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001; 285:2114-20.
33. Schumock GT, Butler MG, Meek PD et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003; 23:113-32.
34. Chenella FC, Klotz TA, Gill MA et al. Comparison of physician and pharmacist management of anticoagulant therapy of inpatients. Am J Hosp Pharm. 1983; 40: 1642-5.
35. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulant clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998; 158: 1641-9.
36. Tschol N, Lai DK, Tilley JA et al. Comparison of physician- and pharmacist-managed warfarin sodium treatment in open heart surgery patients. Can J Cardiol. 2003; 19:1413-7.
37. Ellis RF, Stephens MA, Sharp GB. Evaluation of pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapy. Am J Hosp Pharm. 1992; 49:387-94.
38. Cohen IA, Hutchinson TA, Kirking DM et al. Evaluation of a pharmacist-managed anticoagulation clinic. J Clin Hosp Pharm. 1985; 10:167-75.
39. Winter ME, Herfindal ET, Bernstein LR. Impact of decentralized pharmacokinetics consultation service. Am J Hosp Pharm. 1986; 43:2178-84.
40. Lynch TJ, Possidente CJ, Cioffi WG et al. Multidisciplinary protocol for determining aminoglycoside dosage. Am J Hosp Pharm. 1992; 49:109-15.
41. Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother. 1994; 28:1335-9.
42. Wade WE, McCall CY. Pharmacist-managed aminoglycoside therapy in combination with a beta-lactam agent in the treatment of nosocomial pneumonia in critically ill patients. Pharmacotherapy. 1995; 15:216-9.
43. Gross R, Morgan AS, Kinky DE et al. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis. 2001; 33:289-95.
44. Wade WE, McCall CY. Drug usage evaluation of aminoglycoside-induced nephrotoxicity in a community hospital. Hosp Formul. 1990; 25:1092-6.
45. Dickerson LM, Mainous AG 3rd, Carek PJ. The pharmacist's role in promoting optimal antimicrobial use. Pharmacotherapy. 2000; 20:711-23.
46. Thornton JP, Goff DA, Segal R et al. Impact of a clinical pharmacist on antibiotic prescribing: a multicenter trial. J Pharm Technol. 1991; 7:195-200.
47. Bond CA, Raehl CL, Pitterle ME et al. Health care professional staffing, hospital characteristics, and hospital mortality rates. Pharmacotherapy. 1999; 19:130-8.
48. Bond CA, Raehl CL, Franke T. Clinical pharmacy sendees and hospital mortality rates. Pharmacotherapy. 1999; 19:556-64.
49. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacist staffing, and drug costs in United States hospitals. Pharmacotherapy. 1999; 19:1354-62.
50. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacy staffing, and the total cost of care in United States hospitals. Pharmacotherapy. 2000; 20: 609-21.
51. Bond CA, Raehl CL, Franke T. Interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing. Pharmacotherapy. 2001; 21:129-41.
52. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy. 2002; 22:134-47.
53. Raehl CL, Bond CA, Pitterle ME. 1995 National Clinical Pharmacy Services Study. Pharmacotherapy. 1998; 18:302-26.
54. Raehl CL, Bond CA, Pitterle ME. Hospital pharmacy services in the Great Lakes region. Am J Hosp Pharm. 1990; 47:1283-303.
55. Raehl CL, Bond CA, Pitterle ME. Pharmaceutical services in U.S. hospitals in 1989. Am J Hosp Pharm. 1992; 49:323-46.
56. Bond CA, Raehl CL, Pitterle ME. 1992 National Clinical Pharmacy Services Study. Pharmacotherapy. 1994; 14:282-304.
57. American Hospital Association abridged guide to the Healthcare field. Chicago, IL: American Hospital Association; 1995. Diskettes.
58. ICD-9 CM easy coder. Montgomery, AL: Unicor Medical, Inc.; 1998.
59. Hazzard WR, Blass JP, Ettinger WH et al. Principles of geriatric medicine and gerontology. 4th ed. New York: McGraw-Hill; 1999:940-9,1549-51.
60. Rosko MD, Broyles RW. The economics of health care: a reference handbook. Westport, CT: Greenwood; 1998.
61. Prospective Payment Assessment Commission. Medicare prospective payment and the American health care system. Washington, DC: Health Care Financing Administration, 1990; HCFA publication no. HE 22.21/3:398.
62. Hammond W, Schwartz AH, Campbell MJ et al. Collaborative drug therapy management by pharmacists-2003. Pharmacotherapy. 2003; 23:1210-25.
63. Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rate, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 2004; 24:953-63.
64. Raehl CL, Bond CA. 1998 National Clinical Pharmacy Sendees Study. Pharmacotherapy. 2000; 20:436-60.
65. Summary of the 1999 information submitted to MEDMARx. Rockville, MD: United States Pharmacopeial Convention; 2000:9.
66. Hicks RW, Cousins DD, Williams RL. Summary of information submitted to the MEDMARx in the year 2002: the quest for quality. Rockville, MD: United States Pharmacopeial Convention; 2002:46.
67. Dubois RW, Brooks RH, Rogers WH. Adjusted hospital death rates: a potential screen for quality of medical care. Am J Public Health. 1987; 77:1162-7.
68. Krakauer H, Bailey RC, Skellan KJ et al. Evaluation of the HCFA model for the analysis of mortality following hospitalization. Health Serv Res. 1992; 27:317-35.
69. Hartz AJ, Krakauer H, Kuhn EM et al. Hospital characteristics and mortality rates. N Engl J Med. 1989; 321:1720-5.
70. Keeler EB, Rubenstein LV, Kahn KL et al. Hospital characteristics and quality of care. JAMA 1992; 268:1709-14.
71. Bond CA, Raehl CL, Pitterle ME. Staffing and the cost of clinical and hospital pharmacy services in United States hospitals. Pharmacotherapy. 1999; 19:767-81,
72. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures-2004. Am J Health-Syst Pharm. 2004; 61:145-58.
73. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis. 1984; 149:23-30.
74. Finch RG, Greenwood D, Norrby SR et al., eds. Antibiotic and chemotherapy: anti-infective agents and their use in therapy. New York: Churchill Livingstone; 2003:161.
75. Kelly WN. Potential risks and prevention, part 1: fatal adverse drug events. Am J Health-Syst Pharm. 2001; 58:1317-24.
76. Kelly WN. Potential risks and prevention, part 2: drug-induced permanent disabilities. Am J Health-Syst Pharm. 2001; 58:1325-9.
77. Kelly WN. Potential risks and prevention, part 4: reports of significant adverse drug events. Am J Health-Syst Pharm. 2001; 58:1406-12.
78. ASHP, Pharmacists' services integral to Medicare drug benefit: CMS emphasizes important role of pharmacists in providing a quality drug benefit. www. ashp.com/newsShowArticle.cfm?cfid= 573521&CFToken=44939321&id=4674 (accessed 2004 Oct 19).
79. Bond CA, Raehl CL, Patry R. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy. 2004; 24:427-40.